Does the media refer more to BEAM or CRSP?

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.96 beat CRISPR Therapeutics' score of 0.94 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNLI or BEAM?

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Beam Therapeutics' score of 0.96 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or EDIT?

In the previous week, Editas Medicine had 16 more articles in the media than Beam Therapeutics. MarketBeat recorded 21 mentions for Editas Medicine and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.96 beat Editas Medicine's score of 0.77 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NTLA or BEAM?

In the previous week, Beam Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Beam Therapeutics' score of 0.96 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRME or BEAM?

In the previous week, Beam Therapeutics had 2 more articles in the media than Prime Medicine. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.96 beat Prime Medicine's score of 0.63 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beam Therapeutics (BEAM) Competitors

$29.11 +0.15 (+0.52%)

As of 12:44 PM Eastern

Compare

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

Should you buy Beam Therapeutics stock or one of its competitors? MarketBeat compares Beam Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

How does Beam Therapeutics compare to CRISPR Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.45	-$79.99M	-$0.68	N/A
CRISPR Therapeutics	$3.51M	1,408.28	-$581.60M	-$6.22	N/A

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.96 beat CRISPR Therapeutics' score of 0.94 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus target price of $46.83, indicating a potential upside of 60.77%. CRISPR Therapeutics has a consensus target price of $65.47, indicating a potential upside of 27.75%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Denali Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Denali Therapeutics currently has a consensus target price of $34.25, indicating a potential upside of 76.64%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 60.77%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.31	-$512.54M	-$2.88	N/A
Beam Therapeutics	$139.74M	21.45	-$79.99M	-$0.68	N/A

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Beam Therapeutics' score of 0.96 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Editas Medicine?

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Beam Therapeutics currently has a consensus target price of $46.83, indicating a potential upside of 60.77%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 90.14%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.45	-$79.99M	-$0.68	N/A
Editas Medicine	$40.52M	6.86	-$160.06M	-$1.23	N/A

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Editas Medicine	-281.59%	-677.39%	-58.25%

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Editas Medicine had 16 more articles in the media than Beam Therapeutics. MarketBeat recorded 21 mentions for Editas Medicine and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.96 beat Editas Medicine's score of 0.77 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

How does Beam Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Intellia Therapeutics presently has a consensus target price of $20.25, suggesting a potential upside of 58.08%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 60.77%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.45	-$412.69M	-$3.54	N/A
Beam Therapeutics	$139.74M	21.45	-$79.99M	-$0.68	N/A

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Beam Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat Beam Therapeutics' score of 0.96 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 2 more articles in the media than Prime Medicine. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.96 beat Prime Medicine's score of 0.63 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Prime Medicine currently has a consensus target price of $7.65, indicating a potential upside of 142.86%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 60.77%. Given Prime Medicine's higher probable upside, equities research analysts clearly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.03M	141.04	-$201.14M	-$1.23	N/A
Beam Therapeutics	$139.74M	21.45	-$79.99M	-$0.68	N/A

Summary

Beam Therapeutics beats Prime Medicine on 11 of the 16 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAM vs. The Competition

Export

Metric	Beam Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.00B	$3.26B	$6.26B	$12.44B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-42.84	17.75	22.35	24.23
Price / Sales	21.45	323.71	555.60	126.08
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.39	6.55	9.82	6.73
Net Income	-$79.99M	$24.20M	$3.56B	$336.97M
7 Day Performance	-8.65%	-3.25%	-1.16%	0.79%
1 Month Performance	-5.16%	0.48%	3.85%	5.38%
1 Year Performance	72.57%	47.06%	27.33%	34.55%

Beam Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAM Beam Therapeutics	2.3268 of 5 stars	$29.17 +0.7%	$46.83 +60.6%	+78.9%	$3.00B	$139.74M	N/A	510
CRSP CRISPR Therapeutics	3.188 of 5 stars	$54.19 -3.5%	$65.47 +20.8%	+40.8%	$5.42B	$3.51M	N/A	460	Positive News Insider Trade
DNLI Denali Therapeutics	3.7437 of 5 stars	$20.41 -3.0%	$34.25 +67.8%	+38.6%	$3.34B	$330.53M	N/A	430	Positive News
EDIT Editas Medicine	3.3987 of 5 stars	$3.34 -3.5%	$5.40 +61.7%	+59.3%	$338.76M	$40.52M	N/A	230
NTLA Intellia Therapeutics	3.0012 of 5 stars	$13.73 -2.4%	$20.25 +47.5%	+83.4%	$1.97B	$67.67M	N/A	600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAM) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Which has more volatility and risk, BEAM or CRSP?

Which has preferable valuation and earnings, BEAM or CRSP?

Is BEAM or CRSP more profitable?

Do insiders & institutionals have more ownership in BEAM or CRSP?

Does the media refer more to BEAM or CRSP?

Do analysts rate BEAM or CRSP?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Which has more risk and volatility, DNLI or BEAM?

Do analysts recommend DNLI or BEAM?

Which has preferable valuation & earnings, DNLI or BEAM?

Is DNLI or BEAM more profitable?

Do insiders & institutionals have more ownership in DNLI or BEAM?

Does the media favor DNLI or BEAM?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Do analysts recommend BEAM or EDIT?

Which has preferable earnings & valuation, BEAM or EDIT?

Which has more risk & volatility, BEAM or EDIT?

Is BEAM or EDIT more profitable?

Do institutionals & insiders have more ownership in BEAM or EDIT?

Does the media prefer BEAM or EDIT?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Do insiders and institutionals hold more shares of NTLA or BEAM?

Do analysts rate NTLA or BEAM?

Which has higher earnings & valuation, NTLA or BEAM?

Is NTLA or BEAM more profitable?

Does the media favor NTLA or BEAM?

Which has more volatility & risk, NTLA or BEAM?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Is PRME or BEAM more profitable?

Do insiders and institutionals have more ownership in PRME or BEAM?

Does the media prefer PRME or BEAM?

Which has more risk and volatility, PRME or BEAM?

Do analysts prefer PRME or BEAM?

Which has better valuation and earnings, PRME or BEAM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools